- Home
- INVE vs NOTV Comparison
INVE vs NOTV Comparison
Compare INVE & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- NOTV
- Stock Information
- Founded
- INVE 1990
- NOTV 1974
- Country
- INVE United States
- NOTV United States
- Employees
- INVE N/A
- NOTV N/A
- Industry
- INVE Computer peripheral equipment
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- INVE Technology
- NOTV Health Care
- Exchange
- INVE Nasdaq
- NOTV Nasdaq
- Market Cap
- INVE 74.2M
- NOTV 69.4M
- IPO Year
- INVE 1997
- NOTV 1997
- Fundamental
- Price
- INVE $3.12
- NOTV $2.03
- Analyst Decision
- INVE Strong Buy
- NOTV Strong Buy
- Analyst Count
- INVE 3
- NOTV 1
- Target Price
- INVE $6.50
- NOTV $5.00
- AVG Volume (30 Days)
- INVE 65.8K
- NOTV 770.3K
- Earning Date
- INVE 08-07-2025
- NOTV 08-07-2025
- Dividend Yield
- INVE N/A
- NOTV N/A
- EPS Growth
- INVE N/A
- NOTV N/A
- EPS
- INVE 3.12
- NOTV N/A
- Revenue
- INVE $25,239,000.00
- NOTV $480,402,000.00
- Revenue This Year
- INVE N/A
- NOTV $4.99
- Revenue Next Year
- INVE $9.00
- NOTV $5.39
- P/E Ratio
- INVE $1.01
- NOTV N/A
- Revenue Growth
- INVE N/A
- NOTV N/A
- 52 Week Low
- INVE $2.86
- NOTV $1.15
- 52 Week High
- INVE $4.35
- NOTV $6.48
- Technical
- Relative Strength Index (RSI)
- INVE 45.58
- NOTV 46.28
- Support Level
- INVE $3.10
- NOTV $1.66
- Resistance Level
- INVE $3.25
- NOTV $3.19
- Average True Range (ATR)
- INVE 0.12
- NOTV 0.20
- MACD
- INVE -0.00
- NOTV -0.04
- Stochastic Oscillator
- INVE 14.81
- NOTV 40.11
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.